Novartis inks agreement to buy Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD
Novartis announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus’ lead asset, farabursen, is a …